First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement

Rhea-AI Summary

First Tracks Biotherapeutics (Nasdaq: ANAB) secured commitments of $145 million in a private placement, including $80 million in gross proceeds to the company from sale of 5,791,478 primary shares at $13.81 per share. First Tracks Bio is expected to spin off on April 20, 2026 and to launch with $180 million in cash, providing an estimated two-year cash runway. Proceeds will fund general corporate purposes, including clinical development of ANB033. The financing involves institutional investors and placement agents Leerink, Barclays and UBS.

Positive

• $145M committed private placement
• $80M gross proceeds to First Tracks Bio from primary share sale
• Company to launch with $180M cash, ~two-year cash runway
• Participation from multiple institutional investors and major placement agents

Negative

• Closing is conditioned on the April 20, 2026 spin-off completion
• Gross proceeds are before placement agent fees and expenses
• Securities sold are unregistered and resale restricted until registration or exemption

News Market Reaction – ANAB

-11.68%

14 alerts

-11.68% Session close to close

-7.7% Trough in 35 min

$1.74B Market Cap

0.6x Rel. Volume

In the Mar 27 session, ANAB declined 11.68%, reflecting a significant negative market reaction. Argus tracked a trough of -7.7% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -11.7% in the session following this news. A negative reaction despite the capital...

Analysis

The stock dropped -11.7% in the session following this news. A negative reaction despite the capital commitments could fit a pattern where structuring changes or financings prompt de-risking. Earlier separation news on Mar 3, 2026 saw a 14.61% rise, but insider activity since then has been net selling. Investors may focus on dilution mechanics at the spin-out entity and execution risks for ANB033 when interpreting a sharp downside move.

Key Figures

Private placement size: $145 million Primary gross proceeds: $80 million Launch cash balance: $180 million +5 more

8 metrics

Private placement size $145 million Total private placement commitments for First Tracks Biotherapeutics

Primary gross proceeds $80 million Gross proceeds to First Tracks Bio from sale of Primary Shares

Launch cash balance $180 million Expected cash for First Tracks Bio at launch

Cash runway two-year Indicated cash-runway for First Tracks Biotherapeutics

Primary shares sold 5,791,478 shares First Tracks Bio common stock sold as Primary Shares

Offering price $13.81 per share Price for Primary Shares and Selling Stockholder shares

Secondary shares sold 4,705,576 shares Shares sold by the Selling Stockholder in the placement

Spin-off date April 20, 2026 Expected completion date of First Tracks Bio spin-off

Historical Context

5 past events · Latest: Mar 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 03	Earnings & separation	Positive	+14.6%	Spin-off timing, royalty focus, strong Q4 collaboration revenue and cash position.
Feb 25	Peer regulatory update	Positive	-0.5%	Peer BLA acceptance for imsidolimab in GPP with defined FDA action date.
Feb 05	Investor conferences	Positive	+3.8%	Planned participation in multiple investor conferences and fireside chats.
Jan 08	Litigation update	Neutral	+2.0%	Motion to dismiss anticipatory breach claim in ongoing Tesaro litigation.
Jan 06	Conference presentation	Positive	+3.0%	Announcement of J.P. Morgan Healthcare Conference presentation and webcast access.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent ANAB news, especially around the planned separation and corporate visibility events, has more often coincided with positive price reactions, while a positive peer regulatory catalyst showed a slight divergence.

Recent Company History

Over the past months, Anaptys has focused on separating its royalty business from its clinical pipeline, with a Q2 2026 spin-off of First Tracks Biotherapeutics highlighted on Mar 3, 2026. That update, alongside strong collaboration revenue and cash of $311.6M, saw a 14.61% move higher. Conference participation announcements also aligned with modest gains. A peer’s BLA acceptance for imsidolimab showed a small negative move, indicating not all positive sector news has translated into upside for related names.

Key Terms

private placement, spin-off, placement agents, registration statement, +3 more

7 terms

private placement financial

"have entered into a purchase agreement with certain third-party investors for a $145 million private placement"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

spin-off financial

"completion of the previously announced spin-off of First Tracks Bio from AnaptysBio, Inc."

A spin-off happens when a company creates a new, independent business by separating part of itself, like splitting off a division into its own company. This often happens so the new company can focus better on its own goals or attract different investors. It matters because it can lead to more growth opportunities and clearer focus for both companies.

View in glossary

placement agents financial

"Leerink Partners, Barclays and UBS Investment Bank are acting as placement agents for the financing."

Placement agents are professional intermediaries who help companies, investment funds or governments find and secure investors when selling stocks, bonds or private securities, acting like a matchmaker that introduces sellers to suitable buyers. For investors, the choice of placement agent matters because their network, reputation and negotiating skill affect who gets access, the price and the speed of a deal, and they can introduce conflicts or additional fees that influence returns.

registration statement regulatory

"First Tracks Bio has agreed to file a registration statement with the SEC registering the resale"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

registration regulatory

"may not be reoffered or resold in the United States absent registration or an applicable exemption"

Registration is the formal filing or listing of a company, security, product, or document with a government or regulatory agency so it may be legally offered, sold, or publicly disclosed. Think of it like registering a car before you can drive it: it creates official records, requires certain disclosures, and signals that regulators have at least reviewed basic information. Investors care because registration increases transparency, enables trading or market access, and can materially affect a company’s liquidity, fundraising options, and regulatory risk.

CD122 antagonist medical

"for clinical development of ANB033, a CD122 antagonist."

A CD122 antagonist is a drug that blocks the CD122 protein, a key part of the receptor that immune signals use to activate certain white blood cells. By preventing those signals, the drug can dial down immune activity—useful for treating autoimmune diseases, preventing transplant rejection, or altering anti‑cancer immune responses. Investors care because such a compound’s effectiveness and side‑effect profile drive clinical trial success and commercial potential, like adjusting a thermostat to change a room’s temperature.

common stock financial

"shares of First Tracks Bio’s common stock (the “Primary Shares”)"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Inclusive of $80 million in proceeds from private placement by leading investors
• First Tracks Biotherapeutics to launch with $180 million in cash and two-year cash-runway
  
  

SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its planned spin-off, First Tracks Biotherapeutics, Inc. (“First Tracks Bio”), and EcoR1 Capital (the “Selling Stockholder”) have entered into a purchase agreement with certain third-party investors for a $145 million private placement, before deducting placement agent fees and other expenses.

In the transaction, First Tracks Bio is selling an aggregate of 5,791,478 shares of First Tracks Bio’s common stock (the “Primary Shares”) at a price of $13.81 per share resulting in $80 million in gross proceeds to the company. Closing of the private placement is conditioned on, and is expected to occur upon, the completion of the previously announced spin-off of First Tracks Bio from AnaptysBio, Inc. (“Anaptys”), which is expected to occur on April 20, 2026.

The Selling Stockholder is selling an aggregate of 4,705,576 shares of First Tracks Bio’s common stock, also at a price of $13.81 per share.

First Tracks Bio intends to use the proceeds from the sale of the Primary Shares for general corporate purposes, including for clinical development of ANB033, a CD122 antagonist.

The financing included participation from new and existing investors including 683 Capital Partners, LP, Adage Capital Partners, L.P., Affinity Asset Advisors, LLC, Ally Bridge Group, Janus Henderson Investors, Palo Alto Investors LP, Point72, StemPoint Capital LP, TCGX, Trails Edge Capital Partners, Vestal Point Capital, Woodline Partners LP, a leading mutual fund, and other institutional investors.

Leerink Partners, Barclays and UBS Investment Bank are acting as placement agents for the financing.

The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities will not and have not been registered under the Securities Act of 1933, as amended, and may not be reoffered or resold in the United States absent registration or an applicable exemption from registration requirements. First Tracks Bio has agreed to file a registration statement with the SEC registering the resale of the common stock sold in the transaction.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: whether the financing will close and the timing therefor; and whether the spin-off of First Tracks Bio will occur and the timing therefor. Statements including words such as “plan,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company’s ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company’s ability to fund development activities and achieve development goals, the company’s ability to protect intellectual property, the ability to effect the separation of companies as described herein and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

Investor Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
investors@anaptysbio.com

FAQ

How much did First Tracks Biotherapeutics raise in the March 27, 2026 private placement (ANAB)?

First Tracks Biotherapeutics secured commitments of $145 million in a private placement. According to the company, $80 million of that amount represents gross proceeds from sale of primary shares at $13.81 per share to First Tracks Bio.

When is the First Tracks Biotherapeutics spin-off from Anaptys expected to occur (ANAB)?

The spin-off is expected to occur on April 20, 2026. According to the company, closing of the private placement is conditioned on completion of that spin-off date.

What will First Tracks Biotherapeutics use the $80 million in proceeds for (ANAB)?

First Tracks Bio intends to use proceeds for general corporate purposes, including clinical development of ANB033. According to the company, funding will support near-term clinical programs and operating needs.

What cash runway does First Tracks Biotherapeutics expect at launch after the financing (ANAB)?

First Tracks Bio is expected to launch with $180 million in cash, providing an estimated two-year cash runway. According to the company, this figure reflects combined balance at spin-off and financing proceeds.

Are the shares sold in the First Tracks private placement immediately resellable in the U.S. (ANAB)?

No; the securities were sold in a transaction not involving a public offering and are unregistered and resale-restricted. According to the company, resale requires registration or an applicable exemption under U.S. securities laws.